Usana Health Sciences, Inc. (NYSE: USNA) has announced its preliminary results for the third quarter ending September 27, 2025, with anticipated net sales of approximately $214 million, compared to $200 million in the prior-year period. Earnings from operations for the current-year quarter are expected to be $1.2 million, or 0.6% of net sales, down from $15.6 million in the third quarter of 2024.
The company's direct-to-consumer business, Hiya, experienced softer sales due to lower than anticipated customer acquisition rates during a typically strong quarter. As a result, the company expects Hiya to achieve double-digit sales growth for 2025.
The preliminary consolidated third quarter results are as follows: Net (loss) earnings: ($6.5) million, compared to $10.6 million in the third quarter of 2024 Diluted EPS: ($0.36), compared to $0.56 in the third quarter of 2024 Adjusted diluted EPS: ($0.15), compared to $0.56 in the third quarter of 2024 Adjusted EBITDA: $13.8 million, compared to $24.6 million in the third quarter of 2024
The company expects the fourth quarter to start from a lower base of active customer counts due to the softer-than-anticipated sales and leader productivity during the third quarter. As a result, it anticipates full-year sales to be at or near the lower end of the previously issued outlook range, with earnings per share expected to be below the range.
The company's management commentary document will be posted on the company’s website under the news/events section, and a conference call to discuss the announcement with analysts and institutional investors is scheduled for the following morning after the earnings release.
The preliminary results and views on market trends are subject to change pending the completion of the quarterly review and finalization of the financial statements. Today the company's shares have moved -1.02% to a price of $26.24. If you want to know more, read the company's complete 8-K report here.
